PATENT CLAIM ANALYSIS

Application Number: 16127734
Application Type: Utility
Filing Date: 2018-09
Publication Date: 2019-08
Patent Classification: ["514", "250000"]

Abstract:
Pharmaceutical compositions containing dihydroergotamine (DHE) and methods in which DHE is administered to patients for treatment of migraine without side effects or adverse effects are disclosed. Methods for rapid treatment of migraine with DHE are disclosed comprising: dampening the peak plasma concentration (C max ) and slightly delaying the peak such as to avoid activating the dopaminergic and adrenergic receptors, while achieving sufficient active binding to the serotonin receptors to provide relief from migraine symptoms within a timeframe that permits rapid resolution of migraine symptoms. Inhaler devices suitable for the methods are disclosed. Kits for practicing the methods of invention are disclosed.

Claim (Index 14):
The method of  claim 1 , wherein the C max  of the dihydroergotamine is less than 7,500 pg/ml.

Metadata:
- Claim Count in Document: 41.0
- Percentile: 97.0
- Lexical Diversity: 1.56338
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15471334', '12069667', '12548292', '12839190', '14921860']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8414667383245679
- 35 USC 102 Novelty (BERT): 0.5930754943078527
- Combined Prediction Score: 0.8166276139228964
- Mean Citation Score: 481.344696
- Max Citation Score: 497.494
- Similarity Product: 460.6702511100769

Labels:
- Claim Label 101: 0
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 0
- Label 101 Adjusted: 0

Dataset: test